It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The simplicity and low cost of rapid point-of-care tests greatly facilitate large-scale population testing, which can contribute to controlling the spread of the COVID-19 virus. We evaluated the applicability of a self-testing strategy for SARS-CoV2 in a population-based, cross-sectional study in Cantabria, Spain, between April and May 2020. For the self-testing strategy, participants received the necessary material for the self-collection of blood and performance of a rapid antibody test using lateral flow immunoassay at home without the supervision of healthcare personnel. A total of 1,022 participants were enrolled. Most participants correctly performed the COVID-19 self-test the first time (91.3% [95% CI 89.4–92.9]). Only a minority of the participants (0.7%) needed the help of healthcare personnel, while 6.9% required a second kit delivery, for a total valid test result in 96.9% of the participants. Incorrect use of the self-test was not associated with the educational level, age over 65, or housing area. Prevalence of IgG antibodies against SARS-CoV2 for subjects with a valid rapid test result was 3.1% (95% CI 2.2–4.4), similar to the seroprevalence result obtained using a conventional approach carried out by healthcare professionals. In conclusion, COVID-19 self-testing should be considered as a screening tool.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 University of Cantabria, IDIVAL, Gastroenterology and Hepatology Department, Marqués de Valdecilla University Hospital, Clinical and Translational Digestive Research Group, Santander, Spain (GRID:grid.7821.c) (ISNI:0000 0004 1770 272X)
2 Cantabria University School of Medicine, Division of Epidemiology and Computational Biology, Santander, Spain (GRID:grid.7821.c) (ISNI:0000 0004 1770 272X)
3 Marqués de Valdecilla University Hospital, IDIVAL, Division of Rheumatology, Santander, Spain (GRID:grid.411325.0) (ISNI:0000 0001 0627 4262)
4 Marqués de Valdecilla University Hospital, IDIVAL, University of Cantabria, Department of Internal Medicine, Santander, Spain (GRID:grid.7821.c) (ISNI:0000 0004 1770 272X)
5 Marqués de Valdecilla University Hospital, IDIVAL, Immunology Department, Santander, Spain (GRID:grid.411325.0) (ISNI:0000 0001 0627 4262)
6 Barcelona Institute for Global Health (ISGlobal), Hospital Clínic, University of Barcelona, Barcelona, Spain (GRID:grid.5841.8) (ISNI:0000 0004 1937 0247)